Back to search results

CATBITE: Antibiotic Prophylaxis for Cat Bites on the Hand/Forearm

This study is looking at the best way to prevent infections after a cat bite to the hand or forearm. Researchers are comparing different antibiotic treatments: amoxicillin/clavulanate or a combination of ciprofloxacin and clindamycin, given for either one day or five days. There's also a group receiving a placebo (an inactive substance) to see if antibiotics are truly needed. All participants will also receive standard wound care. The main goal is to see how many people develop an infection within 30 days. You might be able to join if you are 18 or older, have a cat bite on your hand or forearm within the last 24 hours, and speak English. You cannot join if you already have an infection from the bite.

Study design
This is an interventional study with a planned enrollment of 72 participants. It compares different antibiotic regimens and a placebo.
What's involved
Participants will receive either antibiotics or a placebo for 1 or 5 days, along with wound management. Infection incidence will be checked at several points up to 30 days.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in infection incidence at day 2, day 7, day 14, and day 30.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05846399

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

Recruiting
PHASE4Ages 18+InterventionalPrevention
University of Missouri-Columbia
~72 participants
Updated 2025-10-15 on ClinicalTrials.gov
What's tested:Amoxicillin/clavulanateCiprofloxacinClindamycinPlacebo (microcrystalline cellulose)Wound management

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of infection
Measured over Day 30+/-2
+1 more outcome measured

Conditions

Cat Bite
Hand Injuries
Arm Injury
Infection, Bacterial
Anti-bacterial Agents

Explore related trials

Cat BiteHand InjuryInjury of upper extremity

NCT05846399

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Missouri

    Columbia, Missouristudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kevin M Klifto, DO, PharmD · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia

Who to contact

Stephen H Colbert, MD
[email protected]
573-882-2277
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients greater or equal to 18 years of age.
Bitten by a cat.
Location of bite is the hand and/or forearm (distal to elbow).
Presenting \<24 hours following a cat bite to the hand/forearm.
English speaking

Exclusion

Patients who present with active local or systemic infections
Having a fever \>100.4° F or \>38° C)-Received antibiotics within the past 30 days
Received antibiotics within the past 30 days
Patients unwilling to take study medication
Patients unwilling to attend scheduled follow-up evaluations or complete study forms
Pregnant Women
Type I hypersensitivity reaction to any of the study interventions
Immunocompromised patients (primary and secondary immunodeficiencies) Primary
Autoimmune Lymphoproliferative Syndrome (ALPS)
Autoimmune Polyglandular Syndrome type 1 (APS-1)
B-cell Expansion with Nuclear factor kappa-light-chain-enhancer of activated B cells and T-cell Anergy (BENTA) Disease
Caspase Eight Deficiency State (CEDS)
Caspase Recruitment Domain Family Member 9 (CARD9) Deficiency and Other Syndromes of Susceptibility to Candidiasis
Cartilage-hair hypoplasia
Chédiak-Higashi syndrome
Chronic Granulomatous Disease (CGD)
Common Variable Immunodeficiency (CVID)
Complement Deficiencies
Congenital Neutropenia Syndromes
Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) Deficiency
Cyclic neutropenia
DiGeorge syndrome
Dedicator Of Cytokinesis 8 (DOCK8) Deficiency
GATA-binding protein 2 (GATA2) Deficiency
Glycosylation Disorders with Immunodeficiency
Hyper-Immunoglobulin E Syndromes (HIES)
Hyper-Immunoglobulin M Syndromes
Interferon Gamma, Interleukin 12 and Interleukin 23 Deficiencies
Leukocyte Adhesion Deficiency (LAD) Types 1 and 2
Lipopolysaccharide Responsive Beige-Like Anchor Protein (LRBA) Deficiency
Phosphatidylinositol 3-kinase (PI3-Kinase) Disease
Phospholipase C gamma 2 (PLCG2) associated Antibody Deficiency and Immune Dysregulation (PLAID)
Severe Combined Immunodeficiency (SCID)
Selective Immunoglobulin A (IgA) deficiency
Signal transducer and activator of transcription 3 (STAT3) Dominant-Negative Disease
STAT3 Gain-of-Function Disease
Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Wiskott-Aldrich Syndrome (WAS)
X-Linked Agammaglobulinemia (XLA)
X-Linked Lymphoproliferative Disease (XLP)
X-linked magnesium transporter 1 (MAGT1) deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) Disease
Zeta-associated protein 70 (ZAP-70) deficiency
Malnutrition
Uncontrolled Diabetes mellitus
Chronic uremia
Genetic syndromes: trisomy 21
Immunomodulatory, immunosuppressive drug therapy: corticosteroids, calcineurin inhibitors, cytotoxic agents
Systemic lupus erythematosus
Malignancy
Active radiation therapy
Bone marrow ablation
Infectious diseases: human immunodeficiency virus (HIV) infection, Hepatitis

What this trial measures

  • Incidence of infectionDay 30+/-2

    To compare the incidence of infection (skin, soft tissue, joint, bone) between each study arm to determine the effect of antibiotic prophylaxis and duration on cat bites to the hand and/or forearm within 30 days. Infections are defined by, The Centers for Disease Control and Prevention National Healthcare Safety Network.

  • Changes of the incidence of infectionDay 2; Day 7+/-2; Day 14+/-2; Day 30+/-2

    To compare changes of the incidence of infection (skin, soft tissue, joint, bone) between each study arm and within each study arm to determine the effect of antibiotic prophylaxis and duration on cat bites to the hand and/or forearm at different time points. Infections are defined by the The Centers for Disease Control and Prevention National Healthcare Safety Network.